California’s Gynesonics reported raising $3 million in a new debt offering as it pursues development of its VizAblate fibroid treatment device.
Gynesonics said it won an FDA investigational device exemption for its VizAblate system with an outpatient option for treating symptomatic uterine fibroids.
Gynesonics added another $6.3 million to its coffers as it looks to bring the latest iteration of its VizAblate fibroid device to the U.S. market.
Women’s health devices maker Gynesonics landed $21 million in new financing in supports of its ultrasound-guided uterine fibroid ablation system, the company announced today.
The California company plans to use the funds to further clinical and commercial progress for its VizAblate system, a minimally invasive method for treating uterine fibroids and an alternative to hysterectomy.